Home - Products - Apoptosis - Apoptosis - Pamrevlumab

Pamrevlumab

CAS No. 946415-13-0

Pamrevlumab( —— )

Catalog No. M36727 CAS No. 946415-13-0

Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	392	In Stock
10MG	629	In Stock
25MG	938	In Stock
50MG	1274	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Pamrevlumab
Note

Research use only, not for human use.
Brief Description

Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Description

FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Apoptosis
Target

Apoptosis
Recptor

Apoptosis
Research Area

——
Indication

——

Chemical Information

CAS Number

946415-13-0
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

3,4,5-Trihydroxycinn...

3,4,5-Trihydroxycinnamic acid decyl ester, an effective inhibitor of lipid absorption and accumulation, exhibits anti-obesity properties and acts as a pancreatic lipase inhibitor, with an EC50 of approximately 0.9 μM.
JHU395

JHU395 is an orally-bioavailable prodrug of a lipophilic glutamine antagonist (GA), 6-diazo-5-oxo-L-norleucine (DON).
Lexatumumab

Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma.

Sign In Join Free